title: Evaluation of the firebird sirololimus eluting stent in all comers with coronary artery stenosis.
abstract: OBJECTIVE
  Percutaneous coronary intervention (PCI) has been widely used to treat obstructive coronary artery disease. With the advent of drug-eluting stent (DES) in real world registry was proved as promising therapy. The limitation of the use of DES is the limited health care expenditure. We propose the use of Chinese made DES among Thai patients and that this will solve the cost issue. The clinical result of this DES has not been well known.
  
  
  METHODS
  Prospective study from November 2005 to March 2007 using the structured registry form to evaluate the safety and efficacy of new Chinese made Firebird sirolimus eluting stent (Firebird SES) on clinical parameters from in-hospital, 30 days and 12 months or longer term follow-up. End point is major adverse cardiac event (MACE) including death, MI, TLR and CABG at 30 day and cumulative MACE at 12 month follow-up.
  
  
  RESULTS
  Ninety consecutive patients who were treated with Firebird stent implantation (107 target lesions) were analyzed. Angiographic success (defined as < 30% diameter stenosis) was 85%. Procedure success was 77.8%. MACE at 30 day was 16.6%, cumulative MACE at 12 months was 18.8%. There were total 9 deaths during the study period, two deaths occurred at before 30 days, 3 deaths occurred before 12 months and other 4 deaths occurred after 12 months to 1305 days. Eighty patients (88.9%) had either office visit or telephone call follow-up after 12 months, 38 patients (42.2%) underwent clinical driven coronary arteriography, binary restenosis was 26.3%. Shock and smoking history was the analyzed predictor of MACE at follow-up.
  
  
  CONCLUSIONS
  The implantation of Firebird DES in unselected patients (all comers) is safe, effective and could be an alternative choice of stent for Thai patients.
authors.affiliation: Division of Cardiology, Department of Medicine, Faculty of Medicine, Siriraj Hospital and Her Majesty Cardiac Center, Mahidol University, Bangkok, Thailand.
authors.forename: Damras
authors.initials: D
authors.lastname: Tresukosol
authors.forename: Suwatchai
authors.initials: S
authors.lastname: Pornratanarangsi
authors.forename: Chunhakasem
authors.initials: C
authors.lastname: Chotinaiwattarakul
authors.forename: Wiwun
authors.initials: W
authors.lastname: Tungsubutra
authors.forename: Rewat
authors.initials: R
authors.lastname: Phankingthongkum
authors.forename: Nattawut
authors.initials: N
authors.lastname: Wongpraparut
authors.forename: Tippayawan
authors.initials: T
authors.lastname: Lirdwilai
authors.forename: Treenet
authors.initials: T
authors.lastname: Dapang
authors.forename: Pradit
authors.initials: P
authors.lastname: Panchavinnin
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000628:therapy*; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000628:therapy*; D054855:Drug-Eluting Stents / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012042:Registries; D020123:Sirolimus / Q000008:administration & dosage*; D013534:Survival; D013785:Thailand / Q000453:epidemiology; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus